Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
110 hedge funds and large institutions have $523M invested in Astria Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 24 reducing their positions, and 17 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 24
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
7% more funds holding
Funds holding: 103 → 110 (+7)
3.6% more ownership
Funds ownership: 100.15% → 103.75% (+3.6%)
7% more call options, than puts
Call options by funds: $631K | Put options by funds: $591K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $622M → $523M (-$98.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$30.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.9M |
| 3 |
BlackRock
New York
|
+$4.22M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$1.91M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$10.6M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$7.98M |
| 3 |
Millennium Management
New York
|
-$5.97M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.15M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.54M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CFM
126
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$40.7K | -3,700 | Closed |
|
127
Acadian Asset Management
Boston,
Massachusetts
| – | -$26K | -2,411 | Closed |
|
|
NC
128
nVerses Capital
Wellington,
Florida
| – | -$8.81K | -800 | Closed |
|
ATXS Hedge Fund Activity: Q4 2024 in Review
110 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2024, worth a combined $523M — down 16% from $622M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ATXS positions and 17 closed out — a net gain of 8 holders — while 42 added to existing stakes and 24 trimmed.
The largest buyer was FCPM III Services, opening a new position worth an estimated $30.5M. The largest seller was VR Adviser, cutting an estimated $10.6M.
- 110 institutional investors held Astria Therapeutics (ATXS) as of Q4 2024, up from 103 in Q3 2024.
- Funds reported $523M of Astria Therapeutics stock for Q4 2024, down 16% quarter-over-quarter.
- 25 funds opened new Astria Therapeutics positions in Q4 2024 and 17 closed out, a net change of +8 holders.
- The largest Astria Therapeutics buyer in Q4 2024 was FCPM III Services, an estimated $30.5M added.
- The largest Astria Therapeutics seller in Q4 2024 was VR Adviser, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2024.